Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 79,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Recruiting Phase 2 Interventional

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

NCT07527910
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Tirzepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • Coronado, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid

NCT03954210
View directory record Official record
Conditions
Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I), Sleep and Lifestyle Education
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Inborn Errors of Metabolism

NCT00176904
View directory record Official record
Conditions
Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Gaucher's Disease, Fucosidosis, Wolman Disease, Niemann-Pick Disease, Batten Disease, GM1 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth

NCT05230004
View directory record Official record
Conditions
Limb Deficiencies, Pediatric ALL
Interventions
iFIT prosthesis
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
3 Years to 18 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

NCT00039104
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, zoledronic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 30, 2026, 2:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

NCT06680752
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Interventions
ARD103, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
ARCE Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

NCT05024747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
Drug
Lead sponsor
HALEON
Industry
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

NCT05001347
View directory record Official record
Conditions
Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma
Interventions
TJ004309
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 30, 2026, 2:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BrainWeighve App Feasibility Study

NCT05530538
View directory record Official record
Conditions
Weight Loss, Obesity and Overweight
Interventions
BrainWeighve App
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

NCT00545558
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 30, 2026, 2:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

NCT05551858
View directory record Official record
Conditions
Safety Issues, Pain, Pancreas Fibrosis
Interventions
Proglumide, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

NCT00756548
View directory record Official record
Conditions
Colon Cancer
Interventions
BLI850, polyethylene glycol 3350 based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Anaheim, California • Orange, California • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Oct 30, 2026, 2:00 AM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 30, 2026, 2:00 AM EDT
Completed No phase listed Observational

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02322255
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055
View directory record Official record
Conditions
Weight Loss
Interventions
Placebo, VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

NCT01981278
View directory record Official record
Conditions
Healthy
Interventions
Tapentadol ER 250-mg TRF tablet, Tapentadol ER 250-mg PR2 tablet
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
19 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 30, 2026, 2:00 AM EDT
Terminated Phase 2Phase 3 Interventional

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

NCT01774578
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions
Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed
Drug · Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 30, 2026, 2:00 AM EDT
Terminated Phase 1 Interventional

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

NCT01316185
View directory record Official record
Conditions
Hepatitis D
Interventions
EBP921
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
San Francisco, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Results available

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View directory record Official record
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 30, 2026, 2:00 AM EDT
Withdrawn Phase 4 Interventional

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

NCT00636935
View directory record Official record
Conditions
Pneumocystis Carinii Pneumonia
Interventions
Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 30, 2026, 2:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

NCT01769508
View directory record Official record
Conditions
HER2 Positive Esophagogastric Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Lapatinib, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 30, 2026, 2:00 AM EDT
Completed No phase listed Observational

A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test

NCT05331976
View directory record Official record
Conditions
COVID-19, Asymptomatic COVID-19
Interventions
Proof Lab Test System
Diagnostic Test
Lead sponsor
Proof Diagnostics
Industry
Eligibility
2 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Spring Hill, Florida • Statesville, North Carolina • Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 30, 2026, 2:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia

NCT05421689
View directory record Official record
Conditions
Oropharyngeal Dysphagia
Interventions
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR), Placebo
Biological · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 30, 2026, 2:00 AM EDT